Review





Similar Products

95
MedChemExpress ro8191 co treatment group
Effects of FUC and <t>RO8191</t> on cartilage degeneration and JAK2/STAT3 signaling in vivo . Representative (A) H&E-stained full-joint coronal sections and (B) corresponding high-magnification images of articular cartilage from ACLT rats treated with 200 mg/kg FUC, with or without RO8191 (n=6). Representative (C) Safranin O-Fast Green-stained full-joint coronal sections and (D) corresponding high-magnification images showing cartilage proteoglycan content (n=6). (E) OARSI scores of full-joint coronal sections, with corresponding high-magnification views (n=6). (F) Immunohistochemical staining and quantitative analysis of p-JAK2, total JAK2, p-STAT3 and total STAT3 in articular cartilage (n=6). Scale barrs: 200 µm for (A,C) full-joint coronal sections; 100 µm for (B,D) high-magnification sections. Data are presented as the mean ± SD. **P<0.01. ACLT, anterior cruciate ligament transection; FUC, fucoxanthin; OARSI, Osteoarthritis Research Society International; p, phosphorylated; JAK, Janus kinase.
Ro8191 Co Treatment Group, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/co+treatment/RO8191/pmc13280529-57-2-11
Average 95 stars, based on 1 article reviews
ro8191 co treatment group - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier

99
MedChemExpress co treatment
<t>Co-treatment</t> <t>with</t> SL disA and PD-1 blockade confers synergistic antitumor activity (A) Study protocol. Mice were intravenously injected with SL or SL disA in the murine CT26 tumor model. The PD-1 antibody was intravenously administered on day 3 and 10 after bacterial injection. (B) Tumor volumes in each group were monitored every other day; p values were determined by an unpaired two-tailed Student’s t test, ∗ p < 0.05. (C) Kaplan-Meier survival curves from each group. n = 5 for PBS, PD-1, SL, SL+anti-PD-1, and SL disA ; n = 6 for SL disA +PD-1.
Co Treatment, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/co+treatment/H-151/pmc13091351-176-11-24
Average 99 stars, based on 1 article reviews
co treatment - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

97
MedChemExpress co treatment with cholesterol
<t>Co-treatment</t> <t>with</t> SL disA and PD-1 blockade confers synergistic antitumor activity (A) Study protocol. Mice were intravenously injected with SL or SL disA in the murine CT26 tumor model. The PD-1 antibody was intravenously administered on day 3 and 10 after bacterial injection. (B) Tumor volumes in each group were monitored every other day; p values were determined by an unpaired two-tailed Student’s t test, ∗ p < 0.05. (C) Kaplan-Meier survival curves from each group. n = 5 for PBS, PD-1, SL, SL+anti-PD-1, and SL disA ; n = 6 for SL disA +PD-1.
Co Treatment With Cholesterol, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/co+treatment/Cholesterol/pm42263897-78-28-32
Average 97 stars, based on 1 article reviews
co treatment with cholesterol - by Bioz Stars, 2026-10
97/100 stars
  Buy from Supplier

86
Dotmatics Limited co treatment wells
<t>Co-treatment</t> <t>with</t> SL disA and PD-1 blockade confers synergistic antitumor activity (A) Study protocol. Mice were intravenously injected with SL or SL disA in the murine CT26 tumor model. The PD-1 antibody was intravenously administered on day 3 and 10 after bacterial injection. (B) Tumor volumes in each group were monitored every other day; p values were determined by an unpaired two-tailed Student’s t test, ∗ p < 0.05. (C) Kaplan-Meier survival curves from each group. n = 5 for PBS, PD-1, SL, SL+anti-PD-1, and SL disA ; n = 6 for SL disA +PD-1.
Co Treatment Wells, supplied by Dotmatics Limited, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/co+treatment/co+treatment+wells/us12624035-920-20-5
Average 86 stars, based on 1 article reviews
co treatment wells - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

93
MedChemExpress co treatment group
<t>Co-treatment</t> <t>with</t> SL disA and PD-1 blockade confers synergistic antitumor activity (A) Study protocol. Mice were intravenously injected with SL or SL disA in the murine CT26 tumor model. The PD-1 antibody was intravenously administered on day 3 and 10 after bacterial injection. (B) Tumor volumes in each group were monitored every other day; p values were determined by an unpaired two-tailed Student’s t test, ∗ p < 0.05. (C) Kaplan-Meier survival curves from each group. n = 5 for PBS, PD-1, SL, SL+anti-PD-1, and SL disA ; n = 6 for SL disA +PD-1.
Co Treatment Group, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/co+treatment/M2698/pmc13049528-456-47-73
Average 93 stars, based on 1 article reviews
co treatment group - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

94
MedChemExpress lactic acid la co treatment group
<t>Co-treatment</t> <t>with</t> SL disA and PD-1 blockade confers synergistic antitumor activity (A) Study protocol. Mice were intravenously injected with SL or SL disA in the murine CT26 tumor model. The PD-1 antibody was intravenously administered on day 3 and 10 after bacterial injection. (B) Tumor volumes in each group were monitored every other day; p values were determined by an unpaired two-tailed Student’s t test, ∗ p < 0.05. (C) Kaplan-Meier survival curves from each group. n = 5 for PBS, PD-1, SL, SL+anti-PD-1, and SL disA ; n = 6 for SL disA +PD-1.
Lactic Acid La Co Treatment Group, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/co+treatment/Lactic+acid/pm41864487-51-0-15
Average 94 stars, based on 1 article reviews
lactic acid la co treatment group - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

96
Thermo Fisher mg132 co treatment
<t>Co-treatment</t> <t>with</t> SL disA and PD-1 blockade confers synergistic antitumor activity (A) Study protocol. Mice were intravenously injected with SL or SL disA in the murine CT26 tumor model. The PD-1 antibody was intravenously administered on day 3 and 10 after bacterial injection. (B) Tumor volumes in each group were monitored every other day; p values were determined by an unpaired two-tailed Student’s t test, ∗ p < 0.05. (C) Kaplan-Meier survival curves from each group. n = 5 for PBS, PD-1, SL, SL+anti-PD-1, and SL disA ; n = 6 for SL disA +PD-1.
Mg132 Co Treatment, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/co+treatment/MG+132/pm41816998-140-9-13
Average 96 stars, based on 1 article reviews
mg132 co treatment - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier

Image Search Results


Effects of FUC and RO8191 on cartilage degeneration and JAK2/STAT3 signaling in vivo . Representative (A) H&E-stained full-joint coronal sections and (B) corresponding high-magnification images of articular cartilage from ACLT rats treated with 200 mg/kg FUC, with or without RO8191 (n=6). Representative (C) Safranin O-Fast Green-stained full-joint coronal sections and (D) corresponding high-magnification images showing cartilage proteoglycan content (n=6). (E) OARSI scores of full-joint coronal sections, with corresponding high-magnification views (n=6). (F) Immunohistochemical staining and quantitative analysis of p-JAK2, total JAK2, p-STAT3 and total STAT3 in articular cartilage (n=6). Scale barrs: 200 µm for (A,C) full-joint coronal sections; 100 µm for (B,D) high-magnification sections. Data are presented as the mean ± SD. **P<0.01. ACLT, anterior cruciate ligament transection; FUC, fucoxanthin; OARSI, Osteoarthritis Research Society International; p, phosphorylated; JAK, Janus kinase.

Journal: Molecular Medicine Reports

Article Title: Fucoxanthin alleviates chondrocyte inflammation and osteoarthritis by modulating the JAK2/STAT3 signaling pathway

doi: 10.3892/mmr.2026.13933

Figure Lengend Snippet: Effects of FUC and RO8191 on cartilage degeneration and JAK2/STAT3 signaling in vivo . Representative (A) H&E-stained full-joint coronal sections and (B) corresponding high-magnification images of articular cartilage from ACLT rats treated with 200 mg/kg FUC, with or without RO8191 (n=6). Representative (C) Safranin O-Fast Green-stained full-joint coronal sections and (D) corresponding high-magnification images showing cartilage proteoglycan content (n=6). (E) OARSI scores of full-joint coronal sections, with corresponding high-magnification views (n=6). (F) Immunohistochemical staining and quantitative analysis of p-JAK2, total JAK2, p-STAT3 and total STAT3 in articular cartilage (n=6). Scale barrs: 200 µm for (A,C) full-joint coronal sections; 100 µm for (B,D) high-magnification sections. Data are presented as the mean ± SD. **P<0.01. ACLT, anterior cruciate ligament transection; FUC, fucoxanthin; OARSI, Osteoarthritis Research Society International; p, phosphorylated; JAK, Janus kinase.

Article Snippet: For the RO8191 co-treatment group, RO8191 (5 μM; cat. no. HY-W063968; MedChemExpress) was co-administered with FUC via intra-articular injections at the same volume (15 μl per joint) every 3 days for 7 weeks.

Techniques: In Vivo, Staining, Immunohistochemical staining

FUC reduces inflammatory responses associated with JAK2/STAT3 signaling in vitro . Primary rat chondrocytes were stimulated with IL-1β (10 ng/ml, 24 h) and treated with FUC (15 µM) and/or the JAK2 activator RO8191. (A) Western blot analysis and semi-quantitative evaluation of JAK2/STAT3 signaling components and inflammatory/catabolic protein expression (n=3). (B) Reverse transcription-quantitative PCR analysis of IL-6, MMP3, MMP13 and ADAMTS5 (n=3). (C) ELISA analysis of IL-6 secretion. (D) Immunofluorescence staining of MMP3 in chondrocytes with nuclei counterstained with DAPI, and corresponding quantitative fluorescence intensity analysis. Scale bar, 50 µm. Data are presented as the mean ± SD. *P<0.05; **P<0.01. NC, negative control; FUC, fucoxanthin; ADAMTS, a disintegrin and metalloproteinase with thrombospondin motifs; iNOS, inducible nitric oxide synthase; p, phosphorylated; JAK, Janus kinase.

Journal: Molecular Medicine Reports

Article Title: Fucoxanthin alleviates chondrocyte inflammation and osteoarthritis by modulating the JAK2/STAT3 signaling pathway

doi: 10.3892/mmr.2026.13933

Figure Lengend Snippet: FUC reduces inflammatory responses associated with JAK2/STAT3 signaling in vitro . Primary rat chondrocytes were stimulated with IL-1β (10 ng/ml, 24 h) and treated with FUC (15 µM) and/or the JAK2 activator RO8191. (A) Western blot analysis and semi-quantitative evaluation of JAK2/STAT3 signaling components and inflammatory/catabolic protein expression (n=3). (B) Reverse transcription-quantitative PCR analysis of IL-6, MMP3, MMP13 and ADAMTS5 (n=3). (C) ELISA analysis of IL-6 secretion. (D) Immunofluorescence staining of MMP3 in chondrocytes with nuclei counterstained with DAPI, and corresponding quantitative fluorescence intensity analysis. Scale bar, 50 µm. Data are presented as the mean ± SD. *P<0.05; **P<0.01. NC, negative control; FUC, fucoxanthin; ADAMTS, a disintegrin and metalloproteinase with thrombospondin motifs; iNOS, inducible nitric oxide synthase; p, phosphorylated; JAK, Janus kinase.

Article Snippet: For the RO8191 co-treatment group, RO8191 (5 μM; cat. no. HY-W063968; MedChemExpress) was co-administered with FUC via intra-articular injections at the same volume (15 μl per joint) every 3 days for 7 weeks.

Techniques: In Vitro, Western Blot, Expressing, Reverse Transcription, Real-time Polymerase Chain Reaction, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Staining, Fluorescence, Negative Control

Co-treatment with SL disA and PD-1 blockade confers synergistic antitumor activity (A) Study protocol. Mice were intravenously injected with SL or SL disA in the murine CT26 tumor model. The PD-1 antibody was intravenously administered on day 3 and 10 after bacterial injection. (B) Tumor volumes in each group were monitored every other day; p values were determined by an unpaired two-tailed Student’s t test, ∗ p < 0.05. (C) Kaplan-Meier survival curves from each group. n = 5 for PBS, PD-1, SL, SL+anti-PD-1, and SL disA ; n = 6 for SL disA +PD-1.

Journal: Molecular Therapy Oncology

Article Title: Engineered Salmonella -mediated c-di-AMP delivery activates STING to remodel the tumor microenvironment

doi: 10.1016/j.omton.2026.201185

Figure Lengend Snippet: Co-treatment with SL disA and PD-1 blockade confers synergistic antitumor activity (A) Study protocol. Mice were intravenously injected with SL or SL disA in the murine CT26 tumor model. The PD-1 antibody was intravenously administered on day 3 and 10 after bacterial injection. (B) Tumor volumes in each group were monitored every other day; p values were determined by an unpaired two-tailed Student’s t test, ∗ p < 0.05. (C) Kaplan-Meier survival curves from each group. n = 5 for PBS, PD-1, SL, SL+anti-PD-1, and SL disA ; n = 6 for SL disA +PD-1.

Article Snippet: To investigate the STING dependence of SL disA -induced immune activation, co-treatment experiments were performed with the STING inhibitor H-151 (2 μM final concentration; MedChemExpress, USA).

Techniques: Activity Assay, Injection, Two Tailed Test